Relationship Between CD8-dependent Antigen Recognition, T Cell Functional Avidity, and Tumor Cell Recognition

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2008 Oct 7

PMID 18836717

Citations 14

Authors

Tamson V Moore

Gretchen E Lyons

Natasha Brasic

Jeffrey J Roszkowski

Simon Voelkl

Andreas Mackensen

W Martin Kast

I Caroline Le Poole

Michael I Nishimura

Affiliations

Soon will be listed here.

Abstract

Effective immunotherapy using T cell receptor (TCR) gene-modified T cells requires an understanding of the relationship between TCR affinity and functional avidity of T cells. In this study, we evaluate the relative affinity of two TCRs isolated from HLA-A2-restricted, gp100-reactive T cell clones with extremely high functional avidity. Furthermore, one of these T cell clones, was CD4- CD8- indicating that antigen recognition by this clone was CD8 independent. However, when these TCRs were expressed in CD8- Jurkat cells, the resulting Jurkat cells recognized gp100:209-217 peptide loaded T2 cells and had high functional avidity, but could not recognize HLA-A2+ melanoma cells expressing gp100. Tumor cell recognition by Jurkat cells expressing these TCRs could not be induced by exogenously loading the tumor cells with the native gp100:209-217 peptide. These results indicate that functional avidity of a T cell does not necessarily correlate with TCR affinity and CD8-independent antigen recognition by a T cell does not always mean its TCR will transfer CD8-independence to other effector cells. The implications of these findings are that T cells can modulate their functional avidity independent of the affinity of their TCRs.

Citing Articles

Genetic Modification of T Cells for the Immunotherapy of Cancer.

Quinn S, Lenart N, Dronzek V, Scurti G, Hossain N, Nishimura M Vaccines (Basel). 2022; 10(3).

PMID: 35335089 PMC: 8949949. DOI: 10.3390/vaccines10030457.

Cancer Nanopharmaceuticals: Physicochemical Characterization and In Vitro/In Vivo Applications.

Zielinska A, Szalata M, Gorczynski A, Karczewski J, Eder P, Severino P Cancers (Basel). 2021; 13(8).

PMID: 33920840 PMC: 8071188. DOI: 10.3390/cancers13081896.

Constant regulation for stable CD8 T-cell functional avidity and its possible implications for cancer immunotherapy.

Gilfillan C, Hebeisen M, Rufer N, Speiser D Eur J Immunol. 2021; 51(6):1348-1360.

PMID: 33704770 PMC: 8252569. DOI: 10.1002/eji.202049016.

Structurally silent peptide anchor modifications allosterically modulate T cell recognition in a receptor-dependent manner.

Smith A, Alonso J, Ayres C, Singh N, Hellman L, Baker B Proc Natl Acad Sci U S A. 2021; 118(4).

PMID: 33468649 PMC: 7848747. DOI: 10.1073/pnas.2018125118.

Predicting Cross-Reactivity and Antigen Specificity of T Cell Receptors.

Lee C, Salio M, Napolitani G, Ogg G, Simmons A, Koohy H Front Immunol. 2020; 11:565096.

PMID: 33193332 PMC: 7642207. DOI: 10.3389/fimmu.2020.565096.

References

Zeh 3rd H, Dudley M, Rosenberg S, Yang J . High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol. 1999; 162(2):989-94. View

Ortmann B, Copeman J, Lehner P, Sadasivan B, Herberg J, Grandea A . A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science. 1997; 277(5330):1306-9. DOI: 10.1126/science.277.5330.1306. View

Morgan R, Dudley M, Wunderlich J, Hughes M, Yang J, Sherry R . Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314(5796):126-9. PMC: 2267026. DOI: 10.1126/science.1129003. View

Rosenberg S . A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 1999; 10(3):281-7. DOI: 10.1016/s1074-7613(00)80028-x. View

Seliger B . Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother. 2008; 57(11):1719-26. PMC: 11030176. DOI: 10.1007/s00262-008-0515-4. View

Nishimura M, Avichezer D, Custer M, Lee C, Chen C, Parkhurst M . MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. Cancer Res. 2000; 59(24):6230-8. View

Lyons G, Moore T, Brasic N, Li M, Roszkowski J, Nishimura M . Influence of human CD8 on antigen recognition by T-cell receptor-transduced cells. Cancer Res. 2006; 66(23):11455-61. DOI: 10.1158/0008-5472.CAN-06-2379. View

Clay T, Custer M, SACHS J, Hwu P, Rosenberg S, Nishimura M . Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999; 163(1):507-13. View

Minguet S, Swamy M, Alarcon B, Luescher I, Schamel W . Full activation of the T cell receptor requires both clustering and conformational changes at CD3. Immunity. 2006; 26(1):43-54. DOI: 10.1016/j.immuni.2006.10.019. View

10.

Santomasso B, Roberts W, Thomas A, Williams T, Blachere N, Dudley M . A T-cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci U S A. 2007; 104(48):19073-8. PMC: 2141910. DOI: 10.1073/pnas.0704336104. View

11.

Callender G, Rosen H, Roszkowski J, Lyons G, Li M, Moore T . Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition. Hepatology. 2006; 43(5):973-81. DOI: 10.1002/hep.21157. View

12.

Iero M, Squarcina P, Romero P, Guillaume P, Scarselli E, Cerino R . Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide. Cancer Immunol Immunother. 2007; 56(12):1979-91. PMC: 11030693. DOI: 10.1007/s00262-007-0342-z. View

13.

Schamel W, Risueno R, Minguet S, Ortiz A, Alarcon B . A conformation- and avidity-based proofreading mechanism for the TCR-CD3 complex. Trends Immunol. 2006; 27(4):176-82. DOI: 10.1016/j.it.2006.02.005. View

14.

Kim M, Moon H, Kim K, Lee K . Antigen dose governs the shaping of CTL repertoires in vitro and in vivo. Int Immunol. 2006; 18(3):435-44. DOI: 10.1093/intimm/dxh383. View

15.

Seliger B, Ritz U, Ferrone S . Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer. 2005; 118(1):129-38. DOI: 10.1002/ijc.21312. View

16.

Rosenberg S, Spiess P, Lafreniere R . A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986; 233(4770):1318-21. DOI: 10.1126/science.3489291. View

17.

Cohen C, Li Y, El-Gamil M, Robbins P, Rosenberg S, Morgan R . Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007; 67(8):3898-903. PMC: 2147081. DOI: 10.1158/0008-5472.CAN-06-3986. View

18.

Cawthon A, Alexander-Miller M . Optimal colocalization of TCR and CD8 as a novel mechanism for the control of functional avidity. J Immunol. 2002; 169(7):3492-8. DOI: 10.4049/jimmunol.169.7.3492. View

19.

Kuball J, Dossett M, Wolfl M, Ho W, Voss R, Fowler C . Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood. 2006; 109(6):2331-8. PMC: 1852191. DOI: 10.1182/blood-2006-05-023069. View

20.

Gil D, Schrum A, Alarcon B, Palmer E . T cell receptor engagement by peptide-MHC ligands induces a conformational change in the CD3 complex of thymocytes. J Exp Med. 2005; 201(4):517-22. PMC: 1868566. DOI: 10.1084/jem.20042036. View